
Kongens Lyngby
Articles
-
Jan 14, 2025 |
genomebiology.biomedcentral.com | Kongens Lyngby
In this study, we comprehensively analyzed genomes of the Streptomyces genus, sourcing both from the public database and from our newly published dataset [22]. As of 30 June 2023, we obtained accession IDs for 2938 Streptomycetaceae genomes of all qualities from the NCBI RefSeq database (Additional file 1: Table S1, Fig. 1A). We also incorporated 902 newly sequenced [22] high-quality complete actinomycete genomes for a total of 3840 genomes (Additional file 2: Fig. S1).
-
Aug 13, 2024 |
particleandfibretoxicology.biomedcentral.com | A. F |Kongens Lyngby |Ruud J.B
Prior to exposing rats in the main biodistribution study, two pilot studies were performed with CeO2 NM-212 and TiO2 NM-105 ENMs. To set the exposure concentration in the pilot study, multiple-path particle dosimetry (MPPD V3.14) modelling was used to estimate the deposited fractions in the different lung regions (for details see additional file 1). The mass median aerodynamic diameter (MMAD) was assumed around 1.4 μm for both ENMs based on earlier reported values [11, 12, 18, 19].
-
Jul 15, 2024 |
cardiab.biomedcentral.com | Cape Town |Kongens Lyngby
Ethical clearance was issued by the Health Research Ethics Committee (HREC) of Stellenbosch University (South Africa) (N19/03/043, project ID #9521). Strict compliance to ethical guidelines were carried out, as guided by the Declaration of Helsinki, South African Guidelines for Good Clinical Practice, and Medical Research Council Ethical Guidelines for Research. Stored PPP samples from 10 healthy individuals were used as controls for this study.
-
Jun 13, 2024 |
link.springer.com | Kongens Lyngby
AbstractTraditional polyurethane (PU) catalysts, especially dibutyl tin dilaurate, face scrutiny over toxicity concerns, leading to interest in safer alternatives. In an unexpected turn of events, research into a commercially available antibacterial agent revealed that it drastically reduced the pot life of PU coatings.
-
May 22, 2024 |
academic.oup.com | Kongens Lyngby |Biomedical Informatics |Anne Mette |Austrian Agency
The macrolide azithromycin is a critically important clinical antimicrobial,1 increasingly used as an alternative when typical first-line antimicrobials (e.g. quinolones) are no longer effective in the treatment of severe cases of bacterial gastrointestinal infections.2–5 Considering that azithromycin is one of the few available options for treatment of MDR bacteria and that the majority of the azithromycin resistance genes are acquired, the spread of azithromycin resistance could seriously...
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →